Llwytho...
Vorapaxar in the treatment of cardiovascular diseases
Vorapaxar specifically and effectively inhibits protease activated receptor-1 and may reduce thrombin-mediated ischemic events without interfering primary hemostasis. In the TRA-2P-TIMI 50 trial, vorapaxar reduced the risk of primary ischemic outcome but with increased bleeding risk. In the post hoc...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Future Cardiol |
|---|---|
| Prif Awduron: | , , , , , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
Future Medicine Ltd
2020
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8173497/ https://ncbi.nlm.nih.gov/pubmed/32308016 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/fca-2019-0090 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|